Myeloproliferative neoplasms: New translational therapies

Mount Sinai Journal of Medicine

Volumn 77, Issue 6, 2010, Pages 667-683

  Mascarenhas, John ^a   Hoffman, Ronald ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

BCR ABL; chronic myelogenous leukemia; clinical trials; essential thrombocythemia; JAK2 mutation; myeloproliferative neoplasms; polycythemia vera; primary myelofibrosis; stem cell transplantation; tyrosine kinase inhibitors

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AZD 1480; BOSUTINIB; BUSULFAN; CANCER VACCINE; CLADRIBINE; CYTARABINE; DANUSERTIB; DASATINIB; DNA METHYLTRANSFERASE INHIBITOR; HYDROXYUREA; IMATINIB; INCB 018424; INTERFERON; JANUS KINASE 2 INHIBITOR; LENALIDOMIDE; LESTAURTINIB; MELPHALAN; NILOTINIB; OMACETAXINE MEPESUCCINATE; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; SB 1518; TG 101348; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 019; XL 228;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER PALLIATIVE THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DNA METHYLATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TARGETING; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NEUROPATHY; NONHUMAN; PERIPHERAL NEUROPATHY; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PLEURA EFFUSION; POLYCYTHEMIA VERA; QT PROLONGATION; REVIEW; SEDATION; SIDE EFFECT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; GENES, ABL; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA; PRIMARY MYELOFIBROSIS; STEM CELL TRANSPLANTATION; THROMBOCYTHEMIA, ESSENTIAL; TRANSLATIONAL RESEARCH;

EID: 78649658732     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20225     Document Type: Review

References (171)

1. Tefferi A, Vardiman JW., Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
2. Bennett JH., Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood. Edinb Med Surg J 1845; 64: 413-423.
3. Nowell PC, Hungerford DA., A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497.
4. Rowley JD., Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
5. Groffen J, Heisterkamp N., The BCR/ABL hybrid gene. Baillieres Clin Haematol 1987; 1: 983-999.
6. Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al., The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233: 212-214.
7. Gale RP, Cannani E., The molecular biology of chronic myelogenous leukaemia. Br J Haematol 1985; 60: 395-408.
8. Vaquez H., [Sur une forme spéciale de cyanose s'accompagnant d'hyperglobulie excessive et persistante]. CR Soc Biol (Paris) 1892; 44: 384-338. French.
9. Osler W., Chronic cyanosis with polycythaemia and enlarged spleen: a new clinical entity. Am J Med Sci 1903; 1: 143-146.
10. Dameshek W., Some speculations on the myeloproliferative syndromes. Blood 1951; 6: 372-375.
11. Wasserman LR., Polycythemia Vera Study Group: a historical perspective. Semin Hematol 1986; 23: 183-187.
12. Berk PD, Goldberg JD, Donovan PB, et al., Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132-143.
13. Fruchtman SM, Mack K, Kaplan ME, et al., From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997; 34: 17-23.
14. Barosi G, Mesa RA, Thiele J, et al., Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437-438.
15. Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Geneva, Switzerland: World Health Organization Press; 2008.
16. Jemal A, Siegel R, Ward E, et al., Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
17. Sawyers CL., Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
18. Savage DG, Szydlo RM, Goldman JM., Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 1997; 96: 111-116.
19. Kantarjian H, Sawyers C, Hochhaus A, et al., Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
20. Faderl S, Kantarjian HM, Talpaz M., Chronic myelogenous leukemia: update on biology and treatment. Oncology (Williston Park) 1999; 13: 169-184. (Pubitemid 29102693)
21. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst 1997; 89: 1616-1620.
22. Gangat N, Wolanskyj AP, McClure RF, et al., Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21: 270-276.
23. Rozman C, Giralt M, Feliu E, et al., Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67: 2658-2663.
24. Passamonti F, Rumi E, Caramella M, et al., A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 2008; 111: 3383-3387.
25. Cervantes F, Passamonti F, Barosi G., Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 2008; 22: 905-914.
26. Tefferi A., Risk-based management in essential thrombocythemia. In: Hematology 1999. Washington, DC: American Society of Hematology; 1999; 172-177.
27. Dupriez B, Morel P, Demory JL, et al., Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013-1018.
28. Cervantes F, Dupriez B, Pereira A, et al., New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-2901.
29. Mascarenhas J, Hoffman R., Risk adapted approach to the treatment of primary myelofibrosis. Hematology Education: the education program for the annual congress of the European Hematology Association. 2009; 3: 192-199.
30. Tefferi A, Cortes J, Verstovsek S, et al., Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108: 1158-1164. (Pubitemid 44232010)
31. Barosi G, Elliott M, Canepa L, et al., Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002; 43: 2301-2307.
32. Mesa RA, Steensma DP, Pardanani A, et al., A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534-2541.
33. Mesa R, Yao X, Cripe LD, et al., Lenalidomide and prednisone for primary and post polycythemia vera/essential thrombocythemia myelofibrosis (MF): an Eastern Cooperative Oncology Group (ECOG) phase II trial. Paper presented at: American Society of Hematology Annual Meeting; December 6, 2008; San Francisco, CA.
34. Cervantes F, Alvarez-Larrán A, Domingo A, et al., Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005; 129: 771-775.
35. Cervantes F, Alvarez-Larrán A, Hernández-Boluda JC, et al., Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004; 127: 399-403.
36. Rodríguez JN, Martino ML, Diéguez JC, et al., rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia: experience in 6 patients and meta-analytical approach. Haematologica 1998; 83: 616-621.
37. Barosi G, Liberato LN, Guarnone R., Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1993; 83: 365-369. (Pubitemid 23080004)
38. Hasselbalch HC, Clausen NT, Jensen BA., Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin. Am J Hematol 2002; 70: 92-99.
39. Lofvenberg E, Wahlin A., Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 1988; 41: 375-381.
40. Manoharan A, Pitney WR., Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. Scand J Haematol 1984; 33: 453-459.
41. Petti MC, Latagliata R, Spadea T, et al., Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 116: 576-581.
42. Tefferi A, Silverstein MN, Li CY., 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 1997; 99: 352-357.
43. Rondelli D, Barosi G, Bacigalupo A, et al., Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115-4119.
44. Guardiola P, Anderson JE, Bandini G, et al., Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93: 2831-2838.
45. Rondelli D, Boyer MW, Isola LM, et al., First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in the United States: interim analysis of MPD-RC 101 protocol. J Clin Oncol 2010; 28 (suppl 15S):Abstract 6535.
46. O'Brien SG, Guilhot F, Larson RA, et al., Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
47. Deininger MW, Goldman JM, Melo JV., The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
48. Deininger M, O'Brien SG, Guilhot F, et al., International randomized study of interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Paper presented at: American Society of Hematology Annual Meeting; December 5-8, 2009; San Francisco, CA. Abstract 1126.
49. Cortes JE, Jones D, O'Brien S, et al., Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010; 28: 398-404.
50. Cortes JE, Jones D, O'Brien S, et al., Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010; 28: 392-397.
51. Saglio G, Kim DW, Issaragrisil S, et al., Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
52. Kantarjian H, Shah NP, Hochhaus A, et al., Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
53. Quintás-Cardama A, Kantarjian HM, Jones D, et al., Delayed achievement of molecular responses is associated with increased risk of progression among patients with chronic myelogenous leukemia in chronic phase treated with imatinib. Blood 2009; 113: 6315-6321.
54. Shah NP, Nicoll JM, Nagar B, et al., Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125.
55. Gorre ME, Mohammed M, Ellwood K, et al., Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
56. Apperley JF., Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1018-1029.
57. O'Hare T, Walters DK, Stoffregen EP, et al., In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500-4505.
58. Wang L, Giannoudis A, Lane S, et al., Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83: 258-264.
59. White DL, Saunders VA, Dang P, et al., Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 4064-4072.
60. Cortes JE, Kantarjian H, Brümmendorf T, et al., Safety and efficacy of bosutinib (SKI-606) in patients with chronic phase chronic myeloid leukemia following resistance or intolerance to imatinib. J Clin Oncol 2010; 28 (suppl 15S):Abstract 6502.
61. + + leukemias with either failure to multiple TKI therapies or with T315I mutation. Blood 2008; 112:Abstract 3232.
62. Rousselot P, Huguet F, Rea D, et al., Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58-60.
63. Gontarewicz A, Balabanov S, Keller G, et al., Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008; 111: 4355-4364.
64. Copland M, Pellicano F, Richmond L, et al., BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008; 111: 2843-2853.
65. Jørgensen HG, Holyoake TL., Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans 2007; 35 (part 5): 1347-1351.
66. Chen Y, Hu Y, Michaels S, et al., Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009; 23: 1446-1454.
67. Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al., A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004; 103: 1037-1042.
68. Abruzzese E, Trawinska MM, Coletta A, et al., Peptide-vaccine treatment associated with TKI therapy in patients with CML is able to induce immunologic, cytogenetic and molecular responses: a single center experience with long-term follow up. Blood 2009; 114:Abstract 2185.
69. Bocchia M, Gentili S, Abruzzese E, et al., Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365: 657-662.
70. Li Z, Qiao Y, Liu B, et al., Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 2005; 11: 4460-4468.
71. Marin D, Mauro M, Goldman J, et al., Preliminary results from a phase 2 trial of AG-858, an autologous heat shock protein-peptide vaccine, in combination with imatinib in patients with chronic phase chronic myeloid leukemia (CML) resistant to prior imatinib monotherapy. Blood 2005; 106:Abstract 1094.
72. Gale RP, Hehlmann R, Zhang MJ, et al., Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood 1998; 91: 1810-1819.
73. Clift RA, Storb R., Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant 1996; 17 (suppl 3): S1-S3.
74. Horowitz MM, Rowlings PA, Passweg JR., Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996; 17 (suppl 3): S5-S6.
75. Weisdorf DJ, Anasetti C, Antin JH, et al., Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002; 99: 1971-1977.
76. Goldman JM, Apperley JF, Jones L, et al., Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986; 314: 202-207.
77. Hehlmann R, Berger U, Pfirrmann M, et al., Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686-4692. (Pubitemid 46827759)
78. Bittencourt H, Funke V, Fogliatto L, et al., Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. Bone Marrow Transplant 2008; 42: 597-600.
79. Basak G, Torosian T, Snarski E, et al., Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia. Ann Transplant 2010; 15: 68-70.
80. Gratwohl A, Baldomero H, Horisberger B, et al., Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002; 100: 2374-2386.
81. Gratwohl A, Brand R, Apperley J, et al., Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513-521.
82. Radich JP, Gooley T, Bensinger W, et al., HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003; 102: 31-35.
83. Van Rhee F, Szydlo RM, Hermans J, et al., Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 553-560.
84. Goldman JM, Gale RP, Horowitz MM, et al., Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
85. Kolb HJ, Mittermüller J, Clemm C, et al., Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
86. Drobyski WR, Keever CA, Roth MS, et al., Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310-2318.
87. Porter DL, Roth MS, McGarigle C, et al., Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100-106.
88. Ruiz-Argüelles GJ, Tarin-Arzaga LC, Gonzalez-Carrillo ML, et al., Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transplant 2008; 42: 23-28.
89. Gajewski JL, Robinson P., Do affluent societies have the only options for the best therapy? Leukemia 2007; 21: 387-388.
90. James C, Ugo V, Le Couedic JP, et al., A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148. (Pubitemid 40663494)
91. Baxter EJ, Scott LM, Campbell PJ, et al., Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
92. Kralovics R, Passamonti F, Buser AS, et al., A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790. (Pubitemid 40570926)
93. Levine RL, Wadleigh M, Cools J, et al., Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
94. Kundrapu K, Colenberg L, Duhé RJ., Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation. Cell Biochem Biophys 2008; 52: 103-112.
95. Scott LM, Tong W, Levine RL, et al., JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468.
96. Pardanani A, Lasho TL, Finke C, et al., Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007; 21: 1960-1963.
97. Pietra D, Li S, Brisci A, et al., Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008; 111: 1686-1689.
98. Butcher CM, Hahn U, To LB, et al., Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia 2008; 22: 870-873.
99. Lasho TL, Pardanani A, McClure RF, et al., Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 2006; 135: 683-687.
100. Pardanani AD, Levine RL, Lasho T, et al., MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
101. Delhommeau F, Dupont S, Della Valle V, et al., Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
102. Tefferi A, Pardanani A, Lim KH, et al., TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23: 905-911.
103. Carbuccia N, Murati A, Trouplin V, et al., Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009; 23: 2183-2186.
104. Gelsi-Boyer V, Trouplin V, Adelaide J, et al., Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788-800.
105. Boultwood J, Perry J, Pellagatti A, et al., Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010; 24: 1062-1065.
106. Lee SW, Cho YS, Na JM, et al., ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J Biol Chem 2010; 285: 18-29.
107. Tefferi A., Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
108. Lacout C, Pisani DF, Tulliez M, et al., JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652-1660.
109. Wernig G, Mercher T, Okabe R, et al., Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274-4281.
110. Mesa RA., New drugs for the treatment of myelofibrosis. Curr Hematol Malig Rep 2010; 5: 15-21.
111. Mesa RA, Kantarjian H, Tefferi A, et al., Validation of the serial use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for measuring symptomatic improvement: performance in 86 myelofibrosis patients on INCB018424 clinical trial. Blood 2009; 114:Abstract 3917.
112. Verstovsek S, Odenike O, Scott B, et al., Phase I dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis. Blood 2009; 114:Abstract 3905.
113. Kase H, Iwahashi K, Matsuda Y., K-252a, a potent inhibitor of protein kinase C from microbial origin. J Antibiot (Tokyo) 1986; 39: 1059-1065. (Pubitemid 16046365)
114. Smith BD, Levis M, Beran M, et al., Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004; 103: 3669-3676.
115. Hexner EO, Serdikoff C, Jan M, et al., Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008; 111: 5663-5671.
116. Santos FP, Kantarjian HM, Jain N, et al., Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010; 115: 1131-1136.
117. Hexner E, Goldberg JD, Prchal JT, et al., A multicenter, open label phase I/II study of CEP701 (lestaurtinib) in adults with myelofibrosis; a report on phase I: a study of the Myeloproliferative Disorders Research Consortium (MPD-RC). Paper presented at: American Society of Hematology Annual Meeting; December 7, 2009; New Orleans, LA.
118. Moliterno AR, Hexner E, Roboz GJ, et al., An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients. Blood 2009; 114:Abstract 753.
119. Shah NP, Olszynski P, Sokol L, et al., A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. Blood 2008; 112:Abstract 98.
120. Esteller M., Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
121. Silverman LR, McKenzie DR, Peterson BL, et al., Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895-3903.
122. Kantarjian H, Issa JP, Rosenfeld CS, et al., Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
123. Silverman LR, Holland JF, Weinberg RS, et al., Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993; 7 (suppl 1): 21-29.
124. Xu M, Bruno E, Chao J, et al., The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood 2005; 105: 1699-1705.
125. Barosi G, Viarengo G, Pecci A, et al., Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 2001; 98: 3249-3255.
126. Xu M, Bruno E, Chao J, et al., Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood 2005; 105: 4508-4515. (Pubitemid 40720801)
127. Wang X, Zhang W, Ishii T, et al., Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents. Cancer Res 2009; 69: 7612-7618.
128. Quintás-Cardama A, Tong W, Kantarjian H, et al., A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 2008; 22: 965-970.
129. Mesa RA, Verstovsek S, Rivera C, et al., 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 2009; 23: 180-182.
130. Danilov AV, Relias V, Feeney DM, et al., Decitabine is an effective treatment of idiopathic myelofibrosis. Br J Haematol 2009; 145: 131-132.
131. Mascarenhas J, Navada S, Malone A, et al., Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res 2010; 34: 1246-1249.
132. Odenike OM, Godwin JE, Van Besien K, et al., Phase II trial of low dose, subcutaneous decitabine in myelofibrosis. Blood 2008; 112:Abstract 2809.
133. Silverman LR, Verma A, Odchimar-Reissig R, et al., A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium. J Clin Oncol 2008; 26 (suppl):Abstract 7000.
134. Garcia-Manero G, Yang H, Bueso-Ramos C, et al., Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-1066.
135. Galli M, Salmoiraghi S, Golay J, et al., A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma: preliminary results. Blood 2007; 110:Abstract 1175.
136. Golay J, Cuppini L, Leoni F, et al., The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007; 21: 1892-1900.
137. Guerini V, Barbui V, Spinelli O, et al., Selective targeting of the JAK2V617F mutation in polycythemia vera and essential thrombocythemia by ITF2357, a novel histone deacetylase inhibitor. Blood 2007; 110:Abstract 555.
138. Mascarenhas J, Wang X, Rodriguez A, et al., A phase I study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (Post-PV/ET MF). Blood 2009; 114:Abstract 308.
139. Pestka S, Krause CD, Walter MR., Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8-32.
140. Ortaldo JR, Mason A, Rehberg E, et al., Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J Biol Chem 1983; 258: 15011-15015.
141. Carlo-Stella C, Cazzola M, Gasner A, et al., Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 1987; 70: 1014-1019.
142. Castello G, Lerza R, Cerruti A, et al., The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera. Br J Haematol 1994; 87: 621-623.
143. Dudley JM, Westwood N, Leonard S, et al., Primary polycythaemia: positive diagnosis using the differential response of primitive and mature erythroid progenitors to erythropoietin, interleukin 3 and alpha-interferon. Br J Haematol 1990; 75: 188-194.
144. Hino M, Futami E, Okuno S, et al., Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Ann Hematol 1993; 66: 161-162.
145. Massaro P, Foa P, Pomati M, et al., Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone. Am J Hematol 1997; 56: 126-128.
146. Liu E, Jelinek J, Pastore YD, et al., Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 2003; 101: 3294-3301.
147. Wang Q, Miyakawa Y, Fox N, et al., Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000; 96: 2093-2099.
148. Talpaz M, Kantarjian HM, McCredie K, et al., Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065-1069.
149. Bellucci S, Harousseau JL, Brice P, et al., Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet 1988; 2: 960-961.
150. Silver RT., Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet 1988; 2: 403.
151. Glue P, Fang JW, Rouzier-Panis R, et al., Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556-567.
152. Michallet M, Maloisel F, Delain M, et al., Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 2004; 18: 309-315.
153. Kiladjian JJ, Chomienne C, Fenaux P., Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008; 22: 1990-1998.
154. Kiladjian JJ, Cassinat B, Chevret S, et al., Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065-3072.
155. Boise LH, González-Garcia M, Postema CE, et al., Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
156. Tenedini E, Fagioli ME, Vianelli N, et al., Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. Blood 2004; 104: 3126-3135.
157. Silva M, Richard C, Benito A, et al., Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 1998; 338: 564-571.
158. Kaluzhny Y, Yu G, Sun S, et al., BclxL overexpression in megakaryocytes leads to impaired platelet fragmentation. Blood 2002; 100: 1670-1678.
159. Lu M, Zhang W, Yoo D, et al., Treatment with pegylated interferon alpha 2a in combination with the Bcl-Xl inhibitor ABT-737 specifically targets JAK2V617F positive hematopoietic progenitor cells from patients with polycythemia vera. Blood 2009; 114:Abstract 3916.
160. Lu M, Zhang W, Wang J, et al., Treatment in vitro with a combination of Bcl-Xl inhibitor-ABT-737 and a JAK2 inhibitor selectively eliminates JAK2V617F MPN progenitor cells. Blood 2009; 114:Abstract 752.
161. Parikh S, Kantarjian H, Schimmer A, et al., Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk 2010; 10: 285-289.
162. Blobe GC, Schiemann WP, Lodish HF., Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-1358.
163. Dumont N, Arteaga CL., Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 2003; 3: 531-536.
164. Fortunel NO, Hatzfeld A, Hatzfeld JA., Transforming growth factor-beta:
165. Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al., Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994; 88: 9-16.
166. Naka K, Hoshii T, Muraguchi T, et al., TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676-680.
167. Vannucchi AM, Bogani C, Bartalucci N, et al., The mTOR inhibitor, RAD001, inhibits the growth of cells from patients with myeloproliferative neoplasms. Blood 2009; 114:Abstract 2914.
168. Vannucchi AM, Guglielmelli P, Gattoni E, et al., RAD001, an inhibitor of mTOR, shows clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (PPV/PET MF). Blood 2009; 114:Abstract 307.
169. Lilly M, Sandholm J, Cooper JJ, et al., The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene 1999; 18: 4022-4031.
170. Fiskus WC, Buckley KM, Rao R, et al., Synergistic activity of co-treatment with PIM1 kinase inhibitor SGI-1776 and histone deacetylase inhibitor panobinostat or heat shock protein 90 inhibitor AUY922 against human CML and myeloproliferative neoplasm (MPN) cells. Blood 2009; 114:Abstract 2651.
171. Wang Y, Fiskus W, Chong DG, et al., Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009; 114: 5024-5033.